January 7, 2021 -- Fujifilm plans to invest more than $2 billion to build a large-scale cell culture manufacturing site for biopharmaceuticals in the U.S.
The company's subsidiary, Fujifilm Diosynth Biotechnologies, will operate the new facility, which will provide drug substance manufacturing, fill-finish and assembly, packaging, and labeling services, according to the firm. The facility will house eight 20,000-L bioreactors with the potential to expand and add 24 more bioreactors of the same size.
The new compound will be located near an existing U.S. Fujifilm site, and is expected to begin operations in the spring of 2025, Fujifilm said.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
